World Market for Cancer Therapeutics and Biotherapeutics, 4th Edition, The

Date: October 22, 2011
Pages: 245
Price:
US$ 3,500.00
License [?]:
Publisher: Kalorama Information
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: W14340DF4A1EN
Leaflet:

Download PDF Leaflet

World Market for Cancer Therapeutics and Biotherapeutics, 4th Edition, The
This Kalorama Information report - The World Market for Cancer Therapeutics and Biotherapeutics, 4th Edition - focuses on several segments for cancer treatment including:
  • Chemotherapy, including-subcategories Alkylating Agents, Antimetabolites, Cytotoxic Agents, Plant Derivatives -Brands such as Elotaxin, Taxotere, Gemzar, Alimta and Temodar with Market Share for each
  • Hormone Therapy: -Subcategories include Corticosteroids, Hormone Agonists/Antagonists, Aromatase Inhibitors and SERMS-Brands such as Arimidex, Casodex, Zoladex, Femara and Lupron with Market Share for each.
  • Immunotherapy and Biotherapy, including: -Monoclonal antibodies, interleukins/interferons, vaccines and other biotherapy-Brands such as Rituxan, Herceptin, Gleevec, Evastin and Erbitux

One of the most promising new approaches in modern cancer treatment is immunotherapy or biotherapy, the development of methods to augment and enhance the body’s natural tendency to defend itself against malignant tumors without damaging healthy tissue. The report devotes particular attention to these new therapies.

This report, Kalorama's fourth complete research effort into the oncology treatments market in the past ten years, provides market size information for the various types of cancers including the following:
  • Bladder
  • Breast
  • Cervical
  • Colorectal
  • Esophageal
  • Head/Neck
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Neuroblastoma
  • Ovarian
  • Pancreatic
  • Prostate
  • Stomach
CHAPTER ONE: EXECUTIVE SUMMARY

Introduction
Scope and Methodology
Size and Growth of the Market
Issues and Trends Affecting Market
Leading Competitors

CHAPTER TWO: INTRODUCTION

What is Cancer
  Biochemistry of Cancer Cells
  Carcinogen Metabolism
  Causes of Cancer Growth
    Environmental Factors, DNA, RNA
    Cellular Oncogenes
    Tumor Suppressor Genes
History and Growth of the Cancer Treatment Market
Industry Structure
  Product Segments and Technology
    Chemotherapy: At a Glance
    Hormone Therapy: At A Glance
    Biotherapy: At A Glance
    Radiation Therapy: At a Glance
Demographics and Statistics
  Global Cancer Statistics
  Demographics
    Aging Population
Life Expectancy and Cancer
  Life Expectancy
  Birth Rates
Description of Cancers
  Bladder Cancer
  Brain Cancer
  Glioblastoma
  Neuroblastoma
  Breast Cancer
  Cervical Cancer
  Colorectal Cancer
  Esophageal Cancer
  Head and Neck
  Kidney
  Leukemia
  Liver
  Lung Cancer
  Lymphoma
  Melanoma
  Multiple Myeloma
  Ovarian Cancer
  Pancreas
  Prostate Cancer
  Stomach Cancer

CHAPTER THREE: CHEMOTHERAPY

Overview
Product Descriptions and Examples
  Alkylating Agents
  Antimetabolites
  Cytotoxic Agents
  Plant Derivatives
Market Size and Growth
  Markets by Product Type
  Markets by Geographical Segments
    U.S. Market
    European Market
    Japan Market
    ROW Market
  Market Data by Indication
Competitive Analysis

CHAPTER FOUR: HORMONE THERAPY

Overview
Product Descriptions and Examples
  Corticosteroids
  Hormone Agonists and Antagonists
  Aromatase Inhibitors
  Selective Estrogen Receptor Modulators (SERMs)
Market Size and Growth
  Markets by Product Type
  Markets by Geographical Segments
    U.S. Market
    Europe Market
    Japan Market
    ROW Market
  Market Data by Indication
Competitive Analysis

CHAPTER FIVE: BIOTHERAPEUTICS

Overview
Product Descriptions and Examples
  Monoclonal Antibodies
  Interleukins/Interferons
  Tyrisoine Kinase Inhibitors
  Other Biotherapeutics
  Radioimmunotherapy
Market Size and Growth
  Markets by Product Type
  Markets by Geographical Segments
    U.S. Market
    Europe Market
    Japan Market
    ROW Market
  Market Data by Indication
Competitive Analysis

CHAPTER SIX: WORLD CANCER THERAPIES: TOTAL MARKET SIZE AND FORECAST

Overview
Total Market Size and Forecast
Geographical Market Distribution
Competitive Landscape

CHAPTER SEVEN: ISSUES AND TRENDS AFFECTING THE CANCER MARKET

Introduction
Insurance and Reimbursement Issues
Cancer Drug Costs
Personalized Medicine
Targeted Cancer Therapy
Pharmacogenomics
Alliances, Acquisitions and Licensing Agreements
Patient-Reported Outcomes
Alcohol’s Affect on Cancer Incidence
Healthy Lifestyles Continue to Show Promise for Cancer Prevention
  Obesity in the U.S.
    U.S. Obesity Rates Differ Among Ethnic Groups
  Outlook for a Healthier U.S. Population
Cancer Trends
Marketing and Distribution Trends
Geographical Trends
  United States
  Europe
  Japan
Elderly Clinical Trial Involvement
Late-Stage Drug Development Trends
  Significant Developments
    Alpharadin
    Afatinib
    Axitinib
    Bosutinib
    Brentuximab
    Carfilzomib
    Crizotinib
    Erwinaze
    Exelbine
    Motesanib
    Omnitarg
    Regorafenib
    Ridaforolimus
    Zaltrap
Recent NDA Activity
New Approvals

CHAPTER EIGHT: CORPORATE PROFILES

Introduction
AstraZeneca plc
Bristol-Myers Squibb Company
Eli Lilly & Company
Johnson & Johnson
Merck & Company, Inc.
Novartis AG
Pfizer, Inc.
Roche
Sanofi

APPENDIX: MAJOR COMPETITORS’ ADDRESSES

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

Table 1-1: World Cancer Market by Product Type (Chemotherapy, Hormone Therapy, Biotherapeutics), 2005-2015
Figure 1-1: World Cancer Market, Market by Product Type (Chemotherapy, Hormone Therapy, Biotherapeutics), 2005-2015
Figure 1-2: World Cancer Market, Market Share by Product Type, 2010

CHAPTER TWO: INTRODUCTION

Table 2-1: Viruses Associated with Cancer in Humans
Figure 2-1: Approved Cancer Therapies in the United States by Primary Indication
Table 2-2: World Cancer Incidence by Selected Types of Cancer, 2010 and 2020, (Lung,Breast, Colon/ Rectum, Stomach, Liver, Prostate, Cervical, Ovarian, Lymphoma, Pancreatic, Melanoma)
Figure 2-2: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2010 and 2020
Table 2-3: Total Cancer Incidence by Sex and Country (Canada, China, France, Germany, India, Italy, Brazil, Russia, Japan, Spain United Kingdom, United States), 2010 Estimates
Figure 2-3: Total Cancer Incidence by Sex and Country(Canada, China, France, Germany, India, Italy, Brazil, Russia, Japan, Spain United Kingdom, United States), 2010 Estimates
Table 2-4: World Population by Selected Geographical Region (Africa, Asia, Europe, North America, Oceania, South America, World), 2010 - 2050
Figure 2-4: World Population by Selected Geographical Region (Africa, Asia, Europe, North America, Oceania, South America, World), 2010–2050
Table 2-5: Percent Population Over 65 by Year and Region, 2010-2050
Figure 2-5: Estimated World Population by Age, 2010 and 2050
Table 2-6: Average Life Expectancy in Years by Country 1980, 2004 and 2009
Figure 2-6: Average Life Expectancy in Years by Country 1980 and 2009
Figure 2-7: United States Average Years of Life Lost Per Person Dying of
Cancer, All Races, Both Sexes, 2006
Figure 2-8: United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both Sexes, 2006
Table 2-7: Crude Birth Rate per 1,000 Persons 2000, 2005 and 2010
Figure 2-9: Crude Birth Rate per 1,000 Persons 2000, 2005 and 2010
Table 2-9: Types of Leukemia
Table 2-9: Types of Primary Lung Cancer
Table 2-10: Classification of Non-Hodgkin’s Lymphomas
Table 2-11: Malignant Conditions of the Skin

CHAPTER THREE: CHEMOTHERAPY

Table 3-1: Leading Products, 2010
Table 3-2: World Chemotherapy Market, 2005-2015
Figure 3-1: World Chemotherapy Market, 2005-2015
Table 3-3: World Chemotherapy Market, Sales by Drug Classification, (Alkylating Agents, Antimetabolites, Cytotoxic agents, Plant Derivatives) 2010
Figure 3-2: World Chemotherapy Market by Drug Classification, (Alkylating Agents, Antimetabolites, Cytotoxic agents, Plant Derivatives)
Table 3-4: World Chemotherapy Market, Sales by Drug Classification (Alkylating Agents, Antimetabolites, Cytotoxic agents, Plant Derivatives), Estimated 2015
Figure 3-3: World Chemotherapy Market by Drug Classification (Alkylating Agents, Antimetabolites, Cytotoxic agents, Plant Derivatives), Estimated 2015
Figure 3-4: World Chemotherapy Current Market by Region (US, EU, Japan, ROW)
Figure 3-5: World Chemotherapy Market by Region 2015 (US, EU, Japan, ROW)
Table 3-5: World Chemotherapy Market Type by Cancer Type (Lung, Breast, Colon, Brain, Ovarian, Other Total)
Figure 3-6: World Chemotherapy Market by Cancer Type (Lung, Breast, Colon, Brain, Ovarian, Other Total)
Table 3-6: World Chemotherapy Market, Leading Suppliers Shares, 2010
Figure 3-7: World Chemotherapy Market, Leading Suppliers Shares, 2010

CHAPTER FOUR: HORMONE THERAPY

Table 4-1: Leading Products, 2010
Table 4-2: World Hormone Therapy Market, 2005-2015
Figure 4-1: World Hormone Therapy Market, 2005-2015
Table 4-3: World Hormone Therapy Market, Sales by Drug Classification (Corticosteroids, Hormone agonists/ Antagonists, Aromatase Inhibitors, SERMs), 2010
Figure 4-2: World Hormone Therapy Market, Market by Drug Classification (Corticosteroids, Hormone agonists/ antagonists, Aromatase inhibitors, SERMs) and Percent Market Share, 2010
Table 4-4: World Hormone Therapy Market, Sales by Drug Classification (Corticosteroids, Hormone agonists/ antagonists, Aromatase inhibitors , SERMs), Estimated 2015
Figure 4-3: World Hormone Therapy Market, Market by Drug Classification (Corticosteroids, Hormone agonists/ antagonists, Aromatase inhibitors, SERMs) and Percent Market Share, 2015
Figure 4-4: World Hormone Therapy Current Market by Region (US, EU, Japan, ROW)
Figure 4-5: World Hormone Therapy Market by Region 2015 (US, EU, Japan, ROW)
Table 4-5: World Hormone Therapy Market by Cancer Type (Breast, Prostate, Other)
Figure 4-6: World Hormone Therapy Market by Cancer Type (Breast, Prostate, Other)
Table 4-6: World Hormone Therapy Market, Leading Suppliers Shares by Market Revenues, 2010
Figure 4-7: World Hormone Therapy Market, Leading Suppliers Market Share, 2010

CHAPTER FIVE: BIOTHERAPEUTICS

Table 5-1: Leading Biopharmaceutical Cancer Treatment Products (Brand Name, Generic Name, Manufacturer/ Marketer, Common Uses, Annual Sales ), 2010
Table 5-2: World Cancer Biotherapeutics Market, 2005-2015
Figure 5-1: World Cancer Biotherapeutics Market, 2005-2015
Table 5-3: World Biotherapeutics Market, Sales by Drug Classification (Monoclonal Antibodies, Interleukins/Interferons, Tyrosine Kinase Inhibitors, Other Biotherapeutics), 2010
Figure 5-2: World Biotherapeutics Market by Drug Classification (Monoclonal Antibodies, Interleukins/Interferons, Tyrosine Kinase Inhibitors, Other Biotherapeutics)
Table 5-4: World Biotherapeutics Market, Drug Classification (Monoclonal Antibodies, Interleukins/Interferons, Tyrosine Kinase Inhibitors, Other Biotherapeutics), 2015
Figure 5-3: World Biotherapeutics Market by Drug Classification (Monoclonal Antibodies, Interleukins/Interferons, Tyrosine Kinase Inhibitors, Other Biotherapeutics), Estimated 2015
Figure 5-4: Cancer Biotherapeutics Market by Region (US, EU, Japan, ROW)
Figure 5-5: Cancer Biotherapeutics Market by Region (US, EU, Japan, ROW), 2015
Table 5-5: World Cancer Biotherapeutics Market by Cancer Type (Colon, Breast, Lymphoma, Leukemia, Others)
Figure 5-6: World Cancer Biotherapeutics Market by Cancer Type(Colon, Breast, Lymphoma, Leukemia, Others)
Table 5-6: World Biotherapeutics Market, Leading Suppliers Shares by Market Revenues, 2010
Figure 5-7: World Cancer Biotherapeutics Market, Leading Suppliers Market Share, 2010

CHAPTER SIX: WORLD CANCER THERAPIES: TOTAL MARKET SIZE AND FORECAST

Table 6-1: World Cancer Market, Market by Product Type, 2005-2015
Figure 6-1: World Cancer Market, Market by Product Type Revenues, 2005-2015
Figure 6-2: World Cancer Market, Market by Product Type and Percent Market Share, 2010
Figure 6-3: World Cancer Market, Market by Product Type and Percent Market Share, 2015
Table 6-2: World Cancer Market, Leading Suppliers’ Shares by Market Revenues, 2010
Figure 6-5: World Cancer Market, Leading Suppliers’ Market Share, 2010

CHAPTER SEVEN: ISSUES AND TRENDS AFFECTING THE CANCER MARKET

Table 7-1: Obesity Rates by U.S. State, 2009
Table 7-2: Select Products in Development by Development Phase
Figure 7-1: Late Stage Cancer Compounds in Development for Major Indications, Distribution Estimates
Table 7-3: Recent NDA Activity: January 2011-July 2011
Table 7-4: Select New Approvals (NCE, Indications, Dosage, Formulations) ,2010-11

CHAPTER EIGHT: CORPORATE PROFILES

Figure 8-1: Late stage Cancer Therapies in Development for Leading Companies
Skip to top


Bladder Cancer Therapeutics: Market Research Report US$ 3,950.00 Oct, 2010 · 580 pages
Prostate Cancer Therapeutics: Market Research Report US$ 4,500.00 Jan, 2016 · 337 pages
Lung Cancer Therapeutics: Market Research Report US$ 3,950.00 Jul, 2009 · 842 pages

Ask Your Question

World Market for Cancer Therapeutics and Biotherapeutics, 4th Edition, The
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: